Menin Inhibitors and the Reshaping of Targeted Leukemia Treatment | Oncology Modality Intelligence | US, EU5, Japan & China

PUBLISHED: August 21, 2026

PAGES: 120 Pages

DELIVERY TIME: 7-10 business days

ADD TO COMPARE

SELECT AN OPTION

Acute leukemia's most genetically defined subsets - KMT2A-rearranged and NPM1-mutant disease - have carried dismal prognoses and few targeted options for years. The menin inhibitors are changing that. The mechanism exploits a dependency these leukemias created for themselves: both subtypes rely on the menin-KMT2A interaction to sustain their transcriptional program, and disrupting it forces differentiation where chemotherapy only bludgeons. Syndax's revumenib opened the class with approval in KMT2A-rearranged leukemia in 2024 and an NPM1-mutant expansion in 2025; Kura Oncology's ziftomenib followed with accelerated approval in November 2025 on the KOMET-001 package. Japan holds a direct stake rather than a spectator's seat: Kyowa Kirin partnered with Kura in November 2024 for ex-US commercialization of ziftomenib including Japan, and Sumitomo Pharma is developing its own Japan-originated menin inhibitor, enzomenib, in early-phase trials. Johnson & Johnson's bleximenib is testing the class's frontier - frontline combinations that would move menin inhibition from salvage therapy into induction regimens. The contested questions now define the class's value. How broad is the treatable population as NPM1 and KMT2A testing spreads, and who owns the diagnostic attach? Will differentiation syndrome and QT considerations constrain community use? Can resistance mutations at the menin interface be engineered around? And how will Japan's hematology infrastructure - from Sysmex's diagnostics position to the academic-center treatment network - absorb a genetically targeted class in a disease area where Japanese drug lag has historically been longest? This report maps the mechanism and the genetic subtypes, the approval precedents and what they establish, the full pipeline from revumenib through the Japanese programs, the testing pathway and its commercial consequences, the frontline-expansion race, and the deal and partnership geometry. It serves hematology business-development teams, diagnostics companies sizing NPM1 and KMT2A testing, investors in the class's sponsors, and Japanese stakeholders holding the country's most direct position in a newly approved drug class.

Scope and Coverage

The report covers menin-KMT2A biology, the revumenib and ziftomenib approvals and their trial packages, the global and Japanese pipeline, frontline-combination development, NPM1/KMT2A diagnostics, and commercialization structures including the Kyowa Kirin-Kura partnership.

Report Highlights

Revumenib (Revuforj): first-in-class approval (2024) and the NPM1 expansion (2025)
Ziftomenib and the KOMET-001 package: accelerated approval (2025) and the Kyowa Kirin partnership
Enzomenib (DSP-5336): Sumitomo Pharma's Japan-originated menin inhibitor
Bleximenib frontline Phase 3 strategy and the move into induction regimens
NPM1/KMT2A testing pathway in Japan: Invivoscribe, Sysmex, and the CDx attach
Resistance biology, differentiation-syndrome management, and combination strategies

Product Code: JPH-110

Table of Content

1. Executive Summary

2. Menin Inhibitors and the Reshaping of Targeted Leukemia Treatment: Modality Overview and Mechanism Landscape

3. Global Pipeline and Deal Activity

4. Key Programs, Clinical Readouts, and Evidence Status

5. Japan Relevance: Trials, Approvals, and Partnerships

6. Regulatory and Pricing Considerations in Japan

7. Competitive Positioning and Valuation Considerations

8. Watch Items and Upcoming Catalysts

9. Appendix: Methodology and Sources

Companies Mentioned

Syndax (US) - revumenib (Revuforj), the first approved menin inhibitor (KMT2A-rearranged 2024; NPM1-mutant expansion 2025); no Japan partner yet
Kura Oncology (US) - ziftomenib, FDA accelerated approval (Nov 2025) on the KOMET-001 package in NPM1-mutant relapsed/refractory AML
Kyowa Kirin (JP) - ziftomenib global partner (Nov 2024) holding ex-US commercialization including Japan
Sumitomo Pharma (JP) - enzomenib (DSP-5336) menin-MLL inhibitor in Phase 1/2; Japan-originated
Johnson & Johnson (US) - bleximenib (JNJ-75276617) in a frontline combination Phase 3
Biomea Fusion (US) - covalent menin-inhibitor program experience with BMF-219
HUTCHMED (CN) - HMPL-506 menin inhibitor in early development
BeiGene (CN) - hematology franchise (zanubrutinib, sonrotoclax) as a China AML market entry point
Invivoscribe (US) - NPM1 MRD and mutation testing for the CDx attach
Sysmex (JP) - Japan hematology-diagnostics infrastructure and the NPM1/KMT2A testing pathway

Product Code: JPH-110

List of Tables

Table 1. Menin-KMT2A biology primer and the genetically defined AML subsets
Table 2. KMT2A-rearranged leukemia: epidemiology, prognosis, and treatment history
Table 3. NPM1-mutant AML: epidemiology, prognosis, and the targeted-therapy gap
Table 4. Revumenib (Revuforj) development history and first-in-class approval (2024)
Table 5. AUGMENT-101 program structure behind the revumenib package
Table 6. Revumenib NPM1-mutant label expansion (2025) and its evidence base
Table 7. Ziftomenib development history and the KOMET-001 registrational package
Table 8. Ziftomenib accelerated approval (2025) in NPM1-mutant relapsed/refractory AML
Table 9. Kyowa Kirin-Kura Oncology partnership (2024): structure and ex-US rights
Table 10. Kyowa Kirin commercialization plan for ziftomenib in Japan
Table 11. Enzomenib (DSP-5336): Sumitomo Pharma's Japan-originated program in Phase 1/2
Table 12. Bleximenib (JNJ-75276617) frontline combination Phase 3 design
Table 13. Biomea Fusion BMF-219 covalent menin-inhibitor program experience
Table 14. HUTCHMED HMPL-506 and the Chinese menin-inhibitor field
Table 15. BeiGene hematology franchise as a China AML market entry platform
Table 16. Menin-interface resistance mutations and next-generation design responses
Table 17. Differentiation syndrome: recognition, management, and protocol frameworks
Table 18. QT-prolongation and drug-interaction management for the class
Table 19. Combination strategies with hypomethylating agents and venetoclax
Table 20. Combination strategies with intensive chemotherapy in frontline settings
Table 21. Maintenance-therapy concepts after transplant and chemotherapy
Table 22. ALL and other disease expansion beyond AML
Table 23. NPM1 mutation testing in Japan: platforms, reimbursement, and practice patterns
Table 24. KMT2A-rearrangement detection: cytogenetics, FISH, and sequencing approaches
Table 25. Invivoscribe NPM1 MRD and mutation-testing products for the CDx attach
Table 26. Sysmex hematology-diagnostics infrastructure and the Japanese testing pathway
Table 27. MRD-guided treatment concepts in menin-inhibitor development
Table 28. Japan AML treatment landscape and the drug-lag context in hematology
Table 29. PMDA pathway considerations for menin-inhibitor filings in Japan
Table 30. Japanese academic-center network for AML trials and its capacity
Table 31. Community-versus-center use considerations for orally administered targeted leukemia drugs
Table 32. NHI pricing framework for genetically targeted leukemia therapies
Table 33. Deal and partnership activity in menin inhibitors, 2023-2026
Table 34. Competitive-position matrix of menin-inhibitor programs
Table 35. Scenario grid for frontline expansion of the class
Table 36. Scenario grid for Japan market formation under Kyowa Kirin commercialization
Table 37. Scenario grid for testing-driven population expansion
Table 38. Risk register for class sponsors
Table 39. Risk register for diagnostics companies dependent on the CDx attach
Table 40. Key opinion leader landscape in Japanese hematology relevant to the class
Table 41. Patient-identification funnel from AML diagnosis to menin-inhibitor eligibility
Table 42. Watchlist of class readouts, filings, and Japan events, 2026-2028
Table 43. Stakeholder map: sponsors, partners, diagnostics firms, societies, and payers
Table 44. Technology-assessment framework for next-generation menin inhibitors
Table 45. Historical analogies: FLT3 and IDH inhibitor rollouts in Japan
Table 46. Partnering-question checklist for companies evaluating the class
Table 47. Valuation frameworks for menin-inhibitor assets post-approval
Table 48. Implications of the class for Japanese AML guideline evolution
Table 49. Key-question tree for hematology BD and investment teams
Table 50. Timeline of menin-inhibitor development from target discovery to approval, 2015-2026

List of Figures

Figure 1. Menin-KMT2A interaction and disruption-mechanism schematic
Figure 2. Genetically defined AML subset map
Figure 3. KMT2A-rearranged disease profile and treatment history
Figure 4. NPM1-mutant disease profile and the targeted gap
Figure 5. Revumenib development arc to first-in-class approval (2024)
Figure 6. AUGMENT-101 program structure
Figure 7. Revumenib NPM1 expansion pathway (2025)
Figure 8. Ziftomenib development arc and the KOMET-001 package
Figure 9. Ziftomenib accelerated-approval pathway (2025)
Figure 10. Kyowa Kirin-Kura partnership map (2024)
Figure 11. Ziftomenib Japan commercialization design
Figure 12. Enzomenib program structure at Sumitomo Pharma
Figure 13. Bleximenib frontline combination strategy
Figure 14. Biomea covalent-inhibitor program experience
Figure 15. Chinese menin-inhibitor landscape including HUTCHMED
Figure 16. BeiGene hematology platform as a China entry vehicle
Figure 17. Resistance-mutation map at the menin interface
Figure 18. Differentiation-syndrome management protocol schematic
Figure 19. QT and drug-interaction management framework
Figure 20. HMA-venetoclax combination architecture with menin inhibitors
Figure 21. Intensive-chemotherapy combination architecture
Figure 22. Maintenance-therapy concept map
Figure 23. Disease-expansion map beyond AML
Figure 24. NPM1 testing pathway in Japan
Figure 25. KMT2A detection methods comparison
Figure 26. Invivoscribe CDx product positioning
Figure 27. Sysmex diagnostics infrastructure and the testing pathway
Figure 28. MRD-guided treatment concepts in class development
Figure 29. Japan AML landscape and the hematology drug-lag context
Figure 30. PMDA pathway for menin-inhibitor filings
Figure 31. Japanese AML trial-network map
Figure 32. Center-versus-community use framework for oral targeted leukemia therapy
Figure 33. NHI pricing frame for genetically targeted leukemia drugs
Figure 34. Menin-inhibitor deal map, 2023-2026
Figure 35. Competitive-position matrix of class programs
Figure 36. Frontline-expansion scenario tree
Figure 37. Japan market-formation scenario tree
Figure 38. Testing-driven population-expansion scenario tree
Figure 39. Risk map for class sponsors
Figure 40. Risk map for diagnostics companies on the CDx attach
Figure 41. Japanese hematology KOL landscape
Figure 42. Patient-identification funnel from diagnosis to eligibility
Figure 43. Class readout, filing, and Japan event calendar, 2026-2028
Figure 44. Stakeholder map across the class
Figure 45. Next-generation menin-inhibitor technology assessment
Figure 46. FLT3 and IDH rollout analogies in Japan
Figure 47. Partnering checklist for the class
Figure 48. Post-approval valuation framework for menin assets
Figure 49. Implications map for Japanese AML guideline evolution
Figure 50. Menin-inhibitor development timeline, 2015-2026